News-Medical.Net on MSN

Novel drug combination overcomes resistance in aggressive KRAS-mutated lung cancer

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and ...
FOX 13 Tampa Bay on MSN

Air Force veteran left in constant pain after lung cancer diagnosis gets life back through trial at Moffitt

Jorge Manchola, a retired Air Force staff sergeant, was diagnosed with stage 4 lung cancer in 2023. The cancer had spread to ...

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally ...
Medscape

FDA Approves Genetic Test for KRAS Mutation in CRC Patients

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...
Rolling Out

Revolutionary cancer vaccine stops deadly KRAS mutations

The deadliest cancers just met their match. A revolutionary cancer vaccine prevents the devastating relapses that have made KRAS-mutated tumors nearly impossible to cure, offering genuine hope to ...
Vietnam Investment Review on MSN

D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002

D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today ...
Business Insider

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence ...
Targeted Oncology

Phase 3 Trial of Calderasib Combo Launched in Advanced KRAS G12C-Mutant NSCLC

The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
EurekAlert!

Hyperactive KRAS mutation triggers cell death in the pancreas

Researchers at MUSC Hollings Cancer Center have discovered why a powerful cancer-causing gene mutation rarely appears in pancreatic tumors. The study, published in Cancer Research Communications, ...